Corporate Statement

Mallinckrodt Pharmaceuticals is a multibillion dollar specialty pharmaceutical company focused on our mission: Listening for Needs. Delivering Solutions. We provide medicines to address unmet patient needs, stemming from 150 years of using our unique strengths, experience and expertise to help improve people’s lives. Discover how our rich history of innovation and patient-centered solutions has helped influence our vision for the future.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Overview

News Releases

01 Nov '22
– Three scientific abstracts highlighting clinical research of terlipressin treatment for adults with HRS involving rapid reduction in kidney function 1  will be presented at the ASN Scientific Meeting, reinforcing Mallinckrodt's ongoing commitment to critically ill patients – DUBLIN , Nov.
24 Oct '22
Trading on NYSE American Expected to Commence Under Ticker Symbol "MNK" on October 27, 2022 DUBLIN , Oct. 24, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has received approval to list
18 Oct '22
DUBLIN , Oct. 18, 2022 /PRNewswire/ -- Mallinckrodt plc  (OTCMKTS: MNKPF ), a global specialty pharmaceutical company, today announced that it will report third quarter 2022 earnings results for the period ended Sept. 30, 2022 , on Tuesday, Nov. 8, 2022 .      A conference call for investors will
go back to the top of the page